Phase I/II Trial of MLN9708 with Lenalidomide and Dexamethasone for Treatment-Naïve Multiple Myeloma


Phase I/II Trial of MLN9708 with Lenalidomide and Dexamethasone for Treatment-Naïve Multiple Myeloma
Slides from a presentation at ASH 2012 and transcribed comments from recent interviews with A Keith Stewart, MBChB (1/9/13) and Kenneth C Anderson, MD (1/22/13)

Kumar S et al. A Phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). Proc ASH 2012;Abstract 332.

Dr Anderson is Kraft Family Professor of Medicine at Harvard Medical School, Director of the Jerome Lipper Multiple Myeloma Center and Director of the LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute in Boston, Massachusetts.

Dr Stewart is Dean for Research at the Mayo Clinic in Arizona, is Consultant in the Division of Hematology/Oncology and holds the Vasek and Anna Maria Polak Professorship in Cancer Research in Scottsdale, Arizona.